Biopartners has presented three-year safety and efficacy trial data in children with growth hormone deficiency for its once-a-week, sustained release recombinant human growth hormone.
The data for the SR-hGH; LB03002 was revealed at the annual meeting of the European Society for Paediatric Endocrinology in Istanbul.
The phase II/III trial data showed that LB03002 in children with GHD demonstrates safety and efficacy profiles comparable with existing, daily human growth hormone products.
Biopartners is also well advanced in its phase III sustained release recombinant human growth hormone trials in children and adults with GHD and is on track to submit a marketing authorisation application to EMEA in 2009.
SR-rhGH (LB03002) is being co-developed by Biopartners and LG Life Sciences.
